2,6-disubstituted-9-cyclopentyl-9H-purines, use thereof as medicaments, and pharmaceutical compositions

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15310%2F21%3A73609335" target="_blank" >RIV/61989592:15310/21:73609335 - isvavai.cz</a>
Result on the web
<a href="https://worldwide.espacenet.com/patent/search/family/068384115/publication/US11028087B2?q=US11028087" target="_blank" >https://worldwide.espacenet.com/patent/search/family/068384115/publication/US11028087B2?q=US11028087</a>
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
2,6-disubstituted-9-cyclopentyl-9H-purines, use thereof as medicaments, and pharmaceutical compositions
Original language description
The present invention relates to novel 2,6-disubstituted-9-cyclopentyl-9H-purines of general formula I, capable of inhibiting the activity of kinases such as FLT3, CDKs and PDGFRs in cancer and other related proliferative diseases. The invention further includes pharmaceutical compositions containing the 2,6-disubstituted-9-cyclpentyl-9H-purines. Compounds of the present invention can be used as active ingredients of a pharmaceutical compositions for treating acute myeloid leukemia (AML).
Czech name
—
Czech description
—

Project
<a href="/en/project/GA19-09086S" target="_blank" >GA19-09086S: Dual FLT3/CDK9 inhibition as a possible therapeutical approach for mixed lineage leukemia</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2021
Confidentiality
C - Předmět řešení projektu podléhá obchodnímu tajemství (§ 504 Občanského zákoníku), ale název projektu, cíle projektu a u ukončeného nebo zastaveného projektu zhodnocení výsledku řešení projektu (údaje P03, P04, P15, P19, P29, PN8) dodané do CEP, jsou upraveny tak, aby byly zveřejnitelné.

Similar results(10)